Overview
This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.
Description
This is a multi-center, prospective, non-interventional, observational study. Subjects will be prescribed in one of the two formulation groups (K-CAB Tab 50 mg or K-CAB ODT 50 mg).
Eligibility
Inclusion Criteria:
- Subjects over 19 years of age as of the date of consent
- Subjects with a total score of 8 or more in the Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) based on Visit 1
- Subjects who voluntarily decides to participate and agrees in writing to the consent form of the study
Exclusion Criteria:
- Subjects who have hypersensitivity reactions and a medical history of Benzimidazole or components of the investigational drug
- Subjects on Atazanavir, Nelfinavir, or Rilpivirine-containing medications
- Pregnant and lactating women


